{"id":499679,"date":"2021-05-28T08:03:31","date_gmt":"2021-05-28T12:03:31","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/morphic-therapeutic-to-present-positive-phase-1-data-for-morf-057-at-ecco21-virtual-congress\/"},"modified":"2021-05-28T08:03:31","modified_gmt":"2021-05-28T12:03:31","slug":"morphic-therapeutic-to-present-positive-phase-1-data-for-morf-057-at-ecco21-virtual-congress","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/morphic-therapeutic-to-present-positive-phase-1-data-for-morf-057-at-ecco21-virtual-congress\/","title":{"rendered":"Morphic Therapeutic to Present Positive Phase 1 Data for MORF-057 at ECCO\u201921 Virtual Congress"},"content":{"rendered":"
\n

\n Presentation will include summary safety, pharmacokinetic and pharmacodynamic data from single ascending dose (SAD), food effect and multiple ascending dose (MAD) studies<\/em>
\n \n <\/p>\n

\n All dosing regimens well-tolerated across Phase 1<\/em>\n <\/p>\n

\n High receptor occupancy (RO) in Phase 1 SAD study confirmed by MAD results with increasing RO over time: receptor saturation at 100 mg BID dose <\/em>\n <\/p>\n

WALTHAM, Mass., May 28, 2021 (GLOBE NEWSWIRE) — Morphic Therapeutic<\/a> (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that new Phase 1 data for MORF-057 will be presented in an ePoster at the Congress of European Crohn\u2019s and Colitis Organisation (ECCO) 2021 Virtual Congress on July 9, 2021.<\/p>\n

The abstract for this e-presentation is now available on the ECCO website and contains data that provide additional support for the tolerability, pharmacokinetic and pharmacodynamic profile of MORF-057 as a twice-daily oral treatment candidate for inflammatory bowel disease (IBD). The complete ePoster is anticipated to report the full Phase 1 results, including data from an additional dose cohort from the MAD study and further pharmacokinetic (PK) endpoint data from a food effect study that were ongoing at the time of abstract submission.<\/p>\n

\u201cThese data confirm the tolerability and pharmacodynamic profile that was reported with the initial MORF-057 SAD data. In these results, we observed \u03b14\u03b27 RO levels that exceeded our expectations across a range of doses, each of which was well tolerated,\u201d said Peter Linde, M.D., chief medical officer at Morphic Therapeutic. \u201cWe are incredibly excited about the results from this Phase 1 study that strongly support our upcoming Phase 2 ulcerative colitis program.\u201d<\/p>\n

Data contained in the abstract demonstrate that single and multiple ascending doses of MORF-057 were well tolerated, with only mild, non-serious adverse events observed. MORF-057 also demonstrated a favorable PK profile with systemic exposure that was predictable and generally proportional to dose. In addition, these MORF-057 clinical data are consistent with non-clinical drug metabolism and PK (DMPK) profiling which will also be presented in a separate poster at the ECCO\u201921 Virtual Congress.<\/p>\n

High levels of target engagement of the \u03b14\u03b27 integrin receptor were observed in the Phase 1 MORF-057 SAD study. As previously reported, the mean \u03b14\u03b27 RO\u2019s for the 100 mg, 150 mg and 400 mg SAD cohorts were greater than 95%. These observations were confirmed in the MAD study, with increasing RO levels at steady state in all doses tested. Increased duration of dosing demonstrated increasing mean RO and decreasing inter-subject RO variability. In these new data, results from two of the three MAD cohorts were available at the time of abstract publication. The mean \u03b14\u03b27 RO for the 50 mg cohort receiving twice-daily (BID) administration of MORF-057 for 14 days was greater than 90% at steady state. The mean \u03b14\u03b27 RO in the 100 mg BID cohort at steady state was greater than 99%, or complete receptor saturation.<\/p>\n

\n MORF-057 Abstracts at ECCO\u201921 Virtual Congress<\/strong>\n <\/p>\n

The full title of the MORF-057 Phase 1 ePoster (P306) is: MORF-057, an oral selective \u03b14\u03b27 integrin inhibitor for Inflammatory Bowel Disease, leads to specific target engagement in a single and multiple ascending dose study in healthy subjects<\/em><\/p>\n

The full title of the MORF-057 non-clinical DMPK ePoster (P037) is: Nonclinical pharmacokinetics and absorption, distribution, metabolism, and excretion properties of MORF-057 support its clinical development as an oral selective \u03b14\u03b27 integrin inhibitor<\/em><\/p>\n

\n About MORF-057<\/strong>\n <\/p>\n

Morphic is developing MORF-057 as a selective, oral small molecule inhibitor of the \u03b14\u03b27 integrin for patients with inflammatory bowel disease (IBD). \u03b14\u03b27 has been clinically validated as a target for the treatment of IBD by the success of the approved injectable antibody therapeutic vedolizumab. MORF-057 is designed to block the interactions between \u03b14\u03b27 on the surface of lymphocytes and the mucosal endothelial cell ligand MAdCAM-1, substantially reducing lymphocyte migration from the bloodstream into intestinal mucosal tissues and causing inflammation that is associated with IBD.<\/p>\n

\n About Morphic Therapeutic<\/strong>
\n
Morphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis and cancer. In collaboration with AbbVie, Janssen, and Schr\u00f6dinger, Morphic is advancing its pipeline and discovery activities using its proprietary Morphic Integrin Technology (MInT) Platform which leverages the Company\u2019s unique understanding of integrin structure and biology. For more information, visit www.morphictx.com<\/a>.<\/p>\n

\n Forward-Looking Statements<\/strong>\n <\/p>\n

This press release contains \u201cforward-looking statements\u201d within the meaning of the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, and of the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: the MInT Platform\u2019s ability to discover drug candidates, Morphic\u2019s plans to develop and commercialize oral small-molecule integrin therapeutics, the execution and completion of the MORF-057 Phase 1 clinical trial as designed, any expectations about safety, efficacy, timing and ability to commence or complete clinical studies and to obtain regulatory approvals for MORF-057 and other candidates in development, the timing of further data presentation and the ability of MORF-057 to treat inflammatory bowel disease or related indications.<\/p>\n

Statements including words such as \u201cbelieve,\u201d \u201cplan,\u201d \u201ccontinue,\u201d \u201cexpect,\u201d \u201cwill,\u201d \u201cdevelop,\u201d \u201csignal,\u201d \u201cpotential,\u201d \u201canticipated,\u201d or \u201congoing\u201d and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements.<\/p>\n

Forward-looking statements are subject to risks and uncertainties that may cause Morphic\u2019s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties in this press release and other risks set forth in our filings with the\u00a0Securities and Exchange Commission, including Morphic\u2019s or a partner\u2019s ability to complete a current or future clinical trial of any of our current or future product candidates, develop or obtain regulatory approval for or commercialize any product candidate, Morphic\u2019s ability to protect intellectual property, the potential impact of the COVID-19 pandemic and the sufficiency of our cash, cash equivalents and investments to fund our operations. These forward-looking statements speak only as of the date hereof and\u00a0Morphic\u00a0specifically disclaims any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise, except as required by law.<\/p>\n

\n Contacts<\/strong>
\n
Morphic Therapeutic
Chris Erdman
chris.erdman@morphictx.com<\/a>
617.686.1718<\/p>\n

Media Contact
Tom Donovan, Ten Bridge Communications
tom@tenbridgecommunications.com<\/a>
857.559.3397<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Presentation will include summary safety, pharmacokinetic and pharmacodynamic data from single ascending dose (SAD), food effect and multiple ascending dose (MAD) studies All dosing regimens well-tolerated across Phase 1 High receptor occupancy (RO) in Phase 1 SAD study confirmed by MAD results with increasing RO over time: receptor saturation at 100 mg BID dose WALTHAM, Mass., May 28, 2021 (GLOBE NEWSWIRE) — Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that new Phase 1 data for MORF-057 will be presented in an ePoster at the Congress of European Crohn\u2019s and Colitis Organisation (ECCO) 2021 Virtual Congress on July 9, 2021. The abstract for this … <\/p>\n

Continue reading “Morphic Therapeutic to Present Positive Phase 1 Data for MORF-057 at ECCO\u201921 Virtual Congress”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-499679","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nMorphic Therapeutic to Present Positive Phase 1 Data for MORF-057 at ECCO\u201921 Virtual Congress - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/morphic-therapeutic-to-present-positive-phase-1-data-for-morf-057-at-ecco21-virtual-congress\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Morphic Therapeutic to Present Positive Phase 1 Data for MORF-057 at ECCO\u201921 Virtual Congress - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Presentation will include summary safety, pharmacokinetic and pharmacodynamic data from single ascending dose (SAD), food effect and multiple ascending dose (MAD) studies All dosing regimens well-tolerated across Phase 1 High receptor occupancy (RO) in Phase 1 SAD study confirmed by MAD results with increasing RO over time: receptor saturation at 100 mg BID dose WALTHAM, Mass., May 28, 2021 (GLOBE NEWSWIRE) — Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that new Phase 1 data for MORF-057 will be presented in an ePoster at the Congress of European Crohn\u2019s and Colitis Organisation (ECCO) 2021 Virtual Congress on July 9, 2021. The abstract for this … Continue reading "Morphic Therapeutic to Present Positive Phase 1 Data for MORF-057 at ECCO\u201921 Virtual Congress"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/morphic-therapeutic-to-present-positive-phase-1-data-for-morf-057-at-ecco21-virtual-congress\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-05-28T12:03:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NDkxNiM0MjA2OTIwIzIxODc0MzU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/morphic-therapeutic-to-present-positive-phase-1-data-for-morf-057-at-ecco21-virtual-congress\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/morphic-therapeutic-to-present-positive-phase-1-data-for-morf-057-at-ecco21-virtual-congress\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Morphic Therapeutic to Present Positive Phase 1 Data for MORF-057 at ECCO\u201921 Virtual Congress\",\"datePublished\":\"2021-05-28T12:03:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/morphic-therapeutic-to-present-positive-phase-1-data-for-morf-057-at-ecco21-virtual-congress\\\/\"},\"wordCount\":1061,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/morphic-therapeutic-to-present-positive-phase-1-data-for-morf-057-at-ecco21-virtual-congress\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0NDkxNiM0MjA2OTIwIzIxODc0MzU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/morphic-therapeutic-to-present-positive-phase-1-data-for-morf-057-at-ecco21-virtual-congress\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/morphic-therapeutic-to-present-positive-phase-1-data-for-morf-057-at-ecco21-virtual-congress\\\/\",\"name\":\"Morphic Therapeutic to Present Positive Phase 1 Data for MORF-057 at ECCO\u201921 Virtual Congress - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/morphic-therapeutic-to-present-positive-phase-1-data-for-morf-057-at-ecco21-virtual-congress\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/morphic-therapeutic-to-present-positive-phase-1-data-for-morf-057-at-ecco21-virtual-congress\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0NDkxNiM0MjA2OTIwIzIxODc0MzU=\",\"datePublished\":\"2021-05-28T12:03:31+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/morphic-therapeutic-to-present-positive-phase-1-data-for-morf-057-at-ecco21-virtual-congress\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/morphic-therapeutic-to-present-positive-phase-1-data-for-morf-057-at-ecco21-virtual-congress\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/morphic-therapeutic-to-present-positive-phase-1-data-for-morf-057-at-ecco21-virtual-congress\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0NDkxNiM0MjA2OTIwIzIxODc0MzU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0NDkxNiM0MjA2OTIwIzIxODc0MzU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/morphic-therapeutic-to-present-positive-phase-1-data-for-morf-057-at-ecco21-virtual-congress\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Morphic Therapeutic to Present Positive Phase 1 Data for MORF-057 at ECCO\u201921 Virtual Congress\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Morphic Therapeutic to Present Positive Phase 1 Data for MORF-057 at ECCO\u201921 Virtual Congress - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/morphic-therapeutic-to-present-positive-phase-1-data-for-morf-057-at-ecco21-virtual-congress\/","og_locale":"en_US","og_type":"article","og_title":"Morphic Therapeutic to Present Positive Phase 1 Data for MORF-057 at ECCO\u201921 Virtual Congress - Market Newsdesk","og_description":"Presentation will include summary safety, pharmacokinetic and pharmacodynamic data from single ascending dose (SAD), food effect and multiple ascending dose (MAD) studies All dosing regimens well-tolerated across Phase 1 High receptor occupancy (RO) in Phase 1 SAD study confirmed by MAD results with increasing RO over time: receptor saturation at 100 mg BID dose WALTHAM, Mass., May 28, 2021 (GLOBE NEWSWIRE) — Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that new Phase 1 data for MORF-057 will be presented in an ePoster at the Congress of European Crohn\u2019s and Colitis Organisation (ECCO) 2021 Virtual Congress on July 9, 2021. The abstract for this … Continue reading \"Morphic Therapeutic to Present Positive Phase 1 Data for MORF-057 at ECCO\u201921 Virtual Congress\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/morphic-therapeutic-to-present-positive-phase-1-data-for-morf-057-at-ecco21-virtual-congress\/","og_site_name":"Market Newsdesk","article_published_time":"2021-05-28T12:03:31+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NDkxNiM0MjA2OTIwIzIxODc0MzU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/morphic-therapeutic-to-present-positive-phase-1-data-for-morf-057-at-ecco21-virtual-congress\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/morphic-therapeutic-to-present-positive-phase-1-data-for-morf-057-at-ecco21-virtual-congress\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Morphic Therapeutic to Present Positive Phase 1 Data for MORF-057 at ECCO\u201921 Virtual Congress","datePublished":"2021-05-28T12:03:31+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/morphic-therapeutic-to-present-positive-phase-1-data-for-morf-057-at-ecco21-virtual-congress\/"},"wordCount":1061,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/morphic-therapeutic-to-present-positive-phase-1-data-for-morf-057-at-ecco21-virtual-congress\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NDkxNiM0MjA2OTIwIzIxODc0MzU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/morphic-therapeutic-to-present-positive-phase-1-data-for-morf-057-at-ecco21-virtual-congress\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/morphic-therapeutic-to-present-positive-phase-1-data-for-morf-057-at-ecco21-virtual-congress\/","name":"Morphic Therapeutic to Present Positive Phase 1 Data for MORF-057 at ECCO\u201921 Virtual Congress - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/morphic-therapeutic-to-present-positive-phase-1-data-for-morf-057-at-ecco21-virtual-congress\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/morphic-therapeutic-to-present-positive-phase-1-data-for-morf-057-at-ecco21-virtual-congress\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NDkxNiM0MjA2OTIwIzIxODc0MzU=","datePublished":"2021-05-28T12:03:31+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/morphic-therapeutic-to-present-positive-phase-1-data-for-morf-057-at-ecco21-virtual-congress\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/morphic-therapeutic-to-present-positive-phase-1-data-for-morf-057-at-ecco21-virtual-congress\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/morphic-therapeutic-to-present-positive-phase-1-data-for-morf-057-at-ecco21-virtual-congress\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NDkxNiM0MjA2OTIwIzIxODc0MzU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NDkxNiM0MjA2OTIwIzIxODc0MzU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/morphic-therapeutic-to-present-positive-phase-1-data-for-morf-057-at-ecco21-virtual-congress\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Morphic Therapeutic to Present Positive Phase 1 Data for MORF-057 at ECCO\u201921 Virtual Congress"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/499679","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=499679"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/499679\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=499679"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=499679"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=499679"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}